News Releases

Return to News

Breaking News from OHC


Clinical Trial Insight: November Lung Cancer Trials

OHC, Blogs, For Physicians, News Releases, 0 comments
November 8, 2013


OHC’s Research Department’s complex clinical trial menu provides an opportunity for patients in and around the Tri-State area to participate in innovative studies that include targeted therapies.

Clinical research into lung cancer has resulted in many recent advances.  Among the most promising and exciting approaches to activating therapeutic anti-tumor immunity is the blockade of immune checkpoints. They are crucial for maintaining self-tolerance and modulating the duration and amplitude of immune responses in peripheral tissues (minimizing collateral tissue damage).

It is now clear that tumors co-opt certain immune-checkpoint pathways as a major mechanism of immune resistance, particularly against T cells that are specific for tumor antigens. T cells is a type of white blood cells called lymphocytes that make up part of the immune system. Because many of the immune checkpoints are initiated by ligand–receptor interactions, they can be readily blocked by antibodies or modulated by recombinant forms of ligands or receptors. Cytotoxic T-lymphocyte-associated antigen 4 (CTLA4) antibodies were the first of this class of immunotherapeutics to achieve U.S. Food and Drug Administration approval (YERVOY® (ipilimumab) full prescribing information, Bristol-Myers Squibb Company).

Preliminary clinical findings with blockers of additional immune checkpoint proteins, such as programmed cell death protein 1 (PD1) and its ligand (PDL-1) indicate broad and diverse opportunities to enhance anti-tumor immunity with the potential to produce durable clinical responses. OHC is excited to be at the forefront of this research.

Clinical trials are currently assessing anti-CTLA4, anti-PD-1 and anti-PDL-1 in a variety of lung cancer settings. For example, OHC is currently participating in a Phase 2, single arm study of MPDL3280A in patients with PDL-1 positive, locally advanced or metastatic non-small cell lung cancer through our partners at the Sarah Cannon Research Institute.

These new targeted trials in lung cancer have gained national and regional attention, with referrals being accepted into OHC from academic and community practices from Cleveland and Akron, Michigan, Kentucky, Indiana and West Virginia for participation in clinical trials.

This clinical trial plan is to enroll 130 patients.

OHC, in partnership with the Sarah Cannon Research Institute (an internationally recognized leader in development of oncologic targeted therapies), offers multiple programs in clinical trial research, focusing within solid organ oncology diseases, including breast, colorectal/rectal, esophageal/gastric, lung (small cell and non-small cell), pancreas, and other varying origins, as well as blood disorders and hematological malignancies.


Comments are closed.